About Us


Shukun Technology is a world leading intelligent healthcare technology platform. With the China-originated global advanced technology, Shukun is dedicated to provide intelligent products and innovation solutions to the healthcare industry.

From the in-house developed leading healthcare smart brain —“ Digital Body” technology platform,Shukun has built the most comprehensive “DigitalDoc” product portfolio, which addresses most of the critical therapeutic areas and serves some of the world’s most prevalent and lethal diseases. The “DigitalDoc” product portfolio has already covered full patient journey from disease screening, to diagnosis and treatment planning processes and has been applied in smart imaging, smart surgery and smart health management fields.

As of today, Shukun is the only company who has obtained NMPA Class III certificates and CE MDR markings in Heart, Brain and Chest therapeutic areas worldwide. 

Shukun has the broadest hospital coverage among AI medical imaging solution providers as well. As of today, the “DigitalDoc” products have been adopted and installed in nearly 3,000 healthcare institutions, including approximately 90% of the Top 100 Hospitals and 60% of all Class III Grade A hospitals in China.

Looking forward, Shukun will further enhance the collaboration with top hospitals,industry experts and research institutions, continue to expand AI and other advance technologies’ application in healthcare area, and empower the digitalization and smartification of the healthcare industry worldwide and ultimately, bring accessible intelligence healthcare services to all human beings.

  • Mission

    To empower a new era of smart healthcare by creating an AI-powered Digital Doctor which assists human doctors to deliver much more efficient, accurate, consistent and accessible patient care.

  • Vision

    Provide accessible smart healthcare services to all human beings.

SHUKUN Milestones
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
Select year
  • Year2022
    • The "DigitalDoc"products have been adopted and installed in nearly 3,000 healthcare institutions

    • Received NMPA Class III certificates for Cerebral CTA, Pneumonia and lung nodule detection software

    • Included in the 2022 "Fortune" China's most socially  impactful start-up companies list

    • Anne Ma, the founder and CEO of Shukun Technology, was selected as one of Forbes China's "2022 China's Top 20 Potential Women in Business" (for the third consecutive year)

  • Year2021
    • Closed Series D round, Goldman Sachs PIA and Primavera were leading investors

    • Launched Digital Abdomen AI

    • Launched Digital Doctor AI platform

    • Received CE Mark for coronary CTA Al, pneumonia Al, Cerebral AI and Lung Nodule AI products

    • Featured in CB Insights most promising health-tech startup

  • Year2020
    • Published R&D results on COVID-19 patient triage decision-making support system on European Respiratory Journal

    • Published R&D results in collaboration with Xuanwu Hospital on Nature Communications; obtained the 12 impact factor in Al medical imaging field

    • Published latest results on Al-assisted quantified forecast of COVID-19 patient disease development on European Respiratory Journal

    • Obtained NMPA Class III certificate for CCTA stenosis triage software

    • Closed Series C round, Sequoia was the leading investor

  • Year2019
    • Completed Series A+ financing Invested by CCV, HUAGAI Capital, etc

    • World's first gold standard multi-center validation, WHO filing

    • Coronary CTA AI products were the national first to undergo the national innovative medical device review pathway

    • Formed strategic partnerships with Philips and GE

    • Obtained NMPA Class II for CCTA stenosis triage software

    • Obtained NMPA Class II for head and neck CT diagnostic software

    • Obtained NMPA Class II for lung nodules diagnostic software

  • Year2018
    • Launched Digital Heart AI

    • Launched Digital Brain AI

    • Coronary CTA Al products clinicall validated in multi-center trials of 40+ hospitals

    • Completed Series A Financing Invested by 5Y Capital, HUAGAI Capital and Marathon Venture Partners

  • Year2017
    • Establishment of Shukun Technology

    • Received angel round investment from Marathon Venture Partners(MVP) 

 Contact Us 
在数坤一展所长 共护人类健康
Contact Us
Request a demo
lnterested in our product?
I have read and fully agree to the terms of Consent to the Personal Information Collection and Instructions

Personal Information Collection and Instructions

Shukun(Beijing) Technology Co.,Ltd. (herein after referred to as “Our Company”) attaches great importance to your privacy and highly appreciates your trust. Our Company would like to inform you the purpose for collecting information, contents of information collected, method that information will be processed, and that you may revoke your authorization at any time.

1. Purpose
(1) To identify the specific person or entity submitting the trial application.
(2) To respond to or provide services for the aforesaid applicant or entity.

2. Collected information
Our Company will collect the following information:
(1) Required information includes: Name, E-mail Address, Country, Phone Number, Job Title, Facility/Company Name, Product Interest, How can we help you?

3. How long will your information be kept?
From the time you authorize Our Company to collect information to the time you revoke the authorization.

4. Refusal to provide information
You are authorized to refuse to provide your information.
If you refuse to provide any of the required information, our Company will not be able to contact you accurately and provide you with our services. Please contact us by other means.
If you refuse to provide any of the optional information, our Company may have difficulties in actively providing you with our services. You may contact us at any time.